nach oben

Clinical Pharmacokinetics

Erschienen in:

27.08.2019 | Letter to the Editor

Comment on: “Levothyrox^® New and Old Formulations: Are they Switchable for Millions of Patients?”

verfasst von: Philippe Lechat, Jacques Ropers, Jérome Barré, Stephane Mouly

Erschienen in: Clinical Pharmacokinetics | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Excerpt

We read with interest the article by Concordet et al. on the analysis of the bioequivalence study between old and new formulations of Levothyrox^®, which was recently published in Clinical Pharmacokinetics [1]. …

Concordet D, Gandia P, Montastruc J-L, Bousquet-Mélou A, Lees P, Ferran A, et al. Levothyrox new and old formulations: are they switchable for millions of patients? Clin Pharmacokinet. 2019;58(7):827–33. https://doi.org/10.1007/s40262-019-00747-3(Epub 4 Apr 2019).CrossRefPubMedPubMedCentral

FDA Guidance document “Statistical Approaches to Establishing Bioequivalence”. 2001. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-approaches-establishing-bioequivalence. Accessed 20 June 2019.

ANSM Levothyrox public report. https://www.ansm.sante.fr/content/download/110115/1395469/version/1/file/Rapport+d%C3%A9valuation+bioequivalence+_+Levothyrox.pdf. Accessed 20 June 2019.

ANSM: Contrôle de la nouvelle formule de Lévothyrox commercialisée à partir de mars 2017: note de synthèse 17-A-12th September 2017. file:///C:/Users/502264/Downloads/Rapport%20danalyse%20Agence%20(CTROL)%20_%20Levothyrox.pdf.

Pharmacovigilance report: third report 6/7/2018 Comité technique de pharmacovigilance du 06/07/2018. http://www.ansm.sante.fr. Accessed 20 June 2019.

Titel: Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”
verfasst von: Philippe Lechat
Jacques Ropers
Jérome Barré
Stephane Mouly
Publikationsdatum: 27.08.2019
Verlag: Springer International Publishing
Erschienen in: Clinical Pharmacokinetics / Ausgabe 10/2019
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-019-00814-9

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2019

Authors’ Reply to Lechat et al.: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”

Physicochemical Properties, Biotransformation, and Transport Pathways of Established and Newly Approved Medications: A Systematic Review of the Top 200 Most Prescribed Drugs vs. the FDA-Approved Drugs Between 2005 and 2016

Assessment of Antiepileptic Drug Concentrations in HIV-Infected versus HIV-Negative Patients: A Retrospective Analysis

Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review

Predictive Value of Microdose Pharmacokinetics